NEW 2026 BULLETINS
Our one-page, easy to understand bulletins are helping patients, families, and practitioners with improving care for AA patients. We are constantly learning and will continue to learn and share the most up to date information we have acquired. New things are being discovered and unfortunately there is great need for treatment options and improvement measures.
Bulletin 2 – Alternative to Low Dose Methylprednisolone-Ketorolac Protocol
Bulletin 3 – Two Types of Pain Relievers: Immediate and Delayed
Bulletin 4 – Enduring Efficacy of Methylprednisolone and Ketorolac for Adhesive Arachnoiditis
Bulletin 5 – At Home Injections for Pain Flares in AA
Bulletin 6 – Spinal Puncture to Adhesive Arachnoiditis: The Process
Bulletin 7 – Sleep Time: An Opportunity for Pain Control
Bulletin 8 – Tennant Protocol for Adhesive Arachnoiditis
Bulletin 10 – Hormone Panel Testing: What, When, Why
Bulletin 11 – Restorative (Anabolic) Hormones: New Element in Pain Care
Bulletin 12 – Fentanyl Patch: Excellent Pain Relief for AA
Bulletin 13 – Long-Acting Opioids are Benefitting Persons with AA
Bulletin 14 – Non-Prescription Alternatives for Corticosteroids and Anti-Inflammatory Agents
Bulletin 15 – Pain Relief: First Step in AA Treatment
Bulletin 16 – Dissolution of Adhesions
Bulletin 17 – Methylene Blue: A New Pain Reliever
Bulletin 18 – Post Delivery Arachnoiditis Case Report
Bulletin 19 – Foundation of Adhesive Arachnoiditis Treatment
Bulletin 20 – Is AA the Worst Pain?
Bulletin 21 – Exercises for Adhesive Arachnoiditis
Bulletin 22 – The 6-Day Medrol Dose Pak and Low Dose Corticosteroids
Bulletin 23 – Why the New Anti-inflammatory Protocol is Superior to the Old One
Bulletin 24 – Neurosteroids Enter Pain Treatment
Bulletin 25 – Do You Have Central Pain?
Bulletin 26 – Constant Pain is a Compilation of Three Types of Pain
Bulletin 27 – Necessity of 3-Component Medical Treatment Program for AA
Bulletin 28 – First Publicized Treatment Study for AA
Bulletin 29 – The New Non-Corticosteroid Treatment for AA
Bulletin 30 – Epstein-Barr Virus Reactivation is Poorly Understood